RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Roivant Sciences Stock

Roivant Sciences Stocks 2024

Roivant Sciences Stocks

831.05 M

Ticker

ROIV

ISIN

BMG762791017

WKN

A3C4MS

In 2024, Roivant Sciences had 831.05 M outstanding stocks, a 16.59% change from the 712.79 M stocks in the previous year.

The Roivant Sciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e831.05
2029e831.05
2028e831.05
2027e831.05
2026e831.05
2025e831.05
2024831.05
2023712.79
2022669.75
2021684.79
2020684.79
2019684.79

Roivant Sciences shares outstanding

The number of shares was Roivant Sciences in 2023 — This indicates how many shares 712.79 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Roivant Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Roivant Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Roivant Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Roivant Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Roivant Sciences Aktienanalyse

What does Roivant Sciences do?

Roivant Sciences Ltd is a biopharmaceutical company based in Basel, Switzerland. It was founded in 2014 by Vivek Ramaswamy, a former hedge fund manager. The company's idea was to develop "orphan molecules," which are drug compounds that have not been further developed by large pharmaceutical companies for various reasons. Roivant Sciences' business model is based on identifying therapy areas with high unmet medical needs. It then collaborates with academic institutions and other partners to search for orphan molecules that could be potentially interesting for these therapy areas. The molecules are further developed in the company's internal research and development laboratories. Roivant Sciences has established seven different subsidiary companies through its innovative approach to drug development and acquisition of other companies. Some of the most well-known subsidiaries include Axovant Sciences, Dermavant Sciences, Enzyvant Therapeutics, and Myovant Sciences. Each subsidiary of Roivant Sciences focuses on specific therapy areas. For example, Axovant Sciences focuses on developing therapies for neurological diseases such as Parkinson's and Alzheimer's, while Dermavant Sciences focuses on dermatology and Enzyvant Therapeutics concentrates on rare genetic diseases. Roivant Sciences has also raised a considerable amount of capital to finance its various companies. In 2017, the company raised $1.1 billion, expanding its presence in the global healthcare market. Products developed by Roivant Sciences' subsidiaries include Axovant's Nelotanserin, a potential medication for hallucinations and nightmares in Parkinson's patients, as well as Myovant's Leuprolide, a medication for treating prostate cancer. The company also has a partnership with Dartmouth College to advance research and development in neuroscience. The partnership aims to identify "specific molecular targets" for developing treatments for neurodegenerative diseases. In summary, Roivant Sciences Ltd is an innovative biopharmaceutical company that develops orphan molecules and specializes in various therapy areas. Its subsidiaries develop products for a range of diseases, from Alzheimer's to prostate cancer and rare genetic disorders. The company has raised a significant amount of capital to finance its operations and collaborates with academic institutions to advance its research and development. Roivant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Roivant Sciences's Shares Outstanding

Roivant Sciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Roivant Sciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Roivant Sciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Roivant Sciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Roivant Sciences stock

How many stocks are there of Roivant Sciences?

The current number of stocks of Roivant Sciences is 831.05 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Roivant Sciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Roivant Sciences evolved in recent years?

The number of shares of Roivant Sciences has increased by 16.59% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Roivant Sciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Roivant Sciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Roivant Sciences pay?

Over the past 12 months, Roivant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Roivant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Roivant Sciences?

The current dividend yield of Roivant Sciences is .

When does Roivant Sciences pay dividends?

Roivant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Roivant Sciences?

Roivant Sciences paid dividends every year for the past 0 years.

What is the dividend of Roivant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Roivant Sciences located?

Roivant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roivant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roivant Sciences from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Roivant Sciences pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Roivant Sciences in the year 2023?

In the year 2023, Roivant Sciences distributed 0 USD as dividends.

In which currency does Roivant Sciences pay out the dividend?

The dividends of Roivant Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Roivant Sciences

Our stock analysis for Roivant Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.